# A Study to Evaluate Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants (MK-4482-011)

> **NCT06615869** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 64 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Molnupiravir

## Key facts

- **NCT ID:** NCT06615869
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-20
- **Primary completion:** 2023-02-27
- **Final completion:** 2023-03-15
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2025-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06615869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06615869, "A Study to Evaluate Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants (MK-4482-011)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06615869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*